

PHAYM001: Preparation for professional practice

[View Online](#)

1

Maher AR. Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in AdultsA Systematic Review and Meta-analysis. JAMA: The Journal of the American Medical Association 2011;**306**. doi:10.1001/jama.2011.1360

2

Clinical guidelines, CG42 - Issued: November 2006. <http://guidance.nice.org.uk/CG42>

3

TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: guidance (MS Word format). <http://guidance.nice.org.uk/TA217/Guidance/doc/English>

4

Exelon - Summary of Product Characteristics (SPC) - (eMC).
<https://www.medicines.org.uk/emc/search?q=Exelon+>

5

Aricept Tablets - Summary of Product Characteristics (SPC) - (eMC).
<http://www.medicines.org.uk/emc/medicine/577/SPC/Aricept>

6

Reminyl Tablets - Summary of Product Characteristics (SPC) - (eMC).

7

Ebixa 5mg/pump actuation oral solution, 20mg and 10 mg Tablets and Treatment Initiation Pack - Summary of Product Characteristics (SPC) - (eMC).

<http://www.medicines.org.uk/EMC/medicine/10175/SPC/rEbixa+5mg+pump+oral+solution%252c+20mg+and+10+mg+tablets+and+Treatment+Initiation+Pack/>

8

DH Living well with dementia: a National Dementia Strategy.

<https://www.gov.uk/government/organisations/department-of-health>

9

British National Formulary. <http://www.bnf.org/bnf/index.htm>

10

Bhasin M, Rowan E, Edwards K, et al. Cholinesterase inhibitors in dementia with Lewy bodies—a comparative analysis. *International Journal of Geriatric Psychiatry* 2007;**22**:890–5. doi:10.1002/gps.1759

11

Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. *The Lancet Neurology* 2007;**6**:782–92. doi:10.1016/S1474-4422(07)70195-3

12

Warner J, Smith T. The rise and fall of antipsychotic prescribing in dementia. Where do we go from here? *The rise and fall of antipsychotic prescribing in dementia*; **14**:24–7.

13

Sube Banerjee. The use of antipsychotic medication for people with dementia: Time for action. A report for the Minister of State for Care Services.

12AD.<http://psychrights.org/research/digest/nlps/BanerjeeReportOnGeriatricNeurolepticUse.pdf>

14

Optimising treatment and care for behavioural and psychological symptoms of dementia: A best practice guide. <https://www.alzheimers.org.uk/bpsdguide>

15

Treatment protocol by NHS Medway: Treatment of Behaviour That Challenges.
<http://www.kmpt.nhs.uk/policies>

16

Antipsychotics increase mortality in elderly patients with dementia.
http://www.npc.nhs.uk/merec/cns/dementia/merec_extra_no39.php

17

Electronic Medicines Compendium (eMC). <http://www.medicines.org.uk/emc/>

18

Pierre N. Tariot, M.D.; Rosemary Erb, R.N., B.S.N.; Carol Ann Podgorski, Ph.D.; Christopher Cox, Ph.D.; Shirish Patel, M.D.; Laura Jakimovich, M.S., R.N.; Carrie Irvine, B.A. Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia. PsychiatryOnline | American Journal of Psychiatry | Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia 1998;**155**:54–61. doi:10.1176/ajp.155.1.54

19

Martinón-Torres G, Fioravanti M, Grimley Evans J. Trazodone for agitation in dementia. Cochrane Database of Systematic Reviews Published Online First: 19 July 2004. doi:10.1002/14651858.CD004990

20

Electronic Medicines Compendium (eMC). <http://www.medicines.org.uk/emc/>

21

Risperdal Tablets, Liquid & Quicklet - Summary of Product Characteristics (SPC) - (eMC).
<http://www.medicines.org.uk/emc/document.aspx?documentid=12818&docType=SPC>

22

Maher AR, Maglione M, Bagley S, et al. Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults. JAMA 2011;**306**.
doi:10.1001/jama.2011.1360

23

Complete Guide to Behavioural and Psychological symptoms of Dementia.
<http://www.ipa-online.org/>

24

Waldemar G, Hyvärinen M, Josiassen MK, et al. Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease. International Journal of Geriatric Psychiatry 2008;**23**:979–81. doi:10.1002/gps.1979

25

Electronic Medicines Compendium (eMC). <https://www.medicines.org.uk/emc/>

26

Evidence Search - Search Engine for Evidence in Health and Social Care.
<https://www.evidence.nhs.uk/>

27

Evidence Search - Search Engine for Evidence in Health and Social Care.
<https://www.evidence.nhs.uk/>

28

Map of Medicine | Home. <http://www.mapofmedicine.com/>

29

Medicines Information - Evidence Search - Search Engine for Evidence in Health and Social Care. <https://www.evidence.nhs.uk/>

30

NPC | National Prescribing Centre. <https://www.guidelinesinpractice.co.uk>

31

National Institute for Health and Care Excellence. <http://www.nice.org.uk/>

32

NICE Clinical Knowledge Summaries (CKS). <http://cks.nice.org.uk/>

33

Scottish Intercollegiate Guidelines Network (SIGN). <http://www.sign.ac.uk/>

34

Centre for Medicines Optimisation - MTRAC | Independent Medicines Review | Midlands Therapeutics Review & Advisory Committee | Centre for Medicines Optimisation | Keele University. <http://centreformedicinesoptimisation.co.uk/mtrac/>

35

NPC | National Prescribing Centre. <https://www.guidelinesinpractice.co.uk>

36

Evidence Search - Search Engine for Evidence in Health and Social Care.
<https://www.evidence.nhs.uk/>

37

GOV.UK. <https://www.gov.uk/government/organisations/department-of-health>

38

Miller WR, Rollnick S. Motivational interviewing: helping people change. 3rd ed. New York: : Guilford Press 2013.

39

Prochaska JO, Norcross JC, DiClemente CC. Changing for good. New York: : William Morrow 1994.

40

Rollnick S, Mason P, Butler C. Health behavior change: a guide for practitioners. Edinburgh: : Churchill Livingstone 1999.

41

Rollnick S, Miller WR, Butler C. Motivational interviewing in health care: helping patients change behavior. New York: : Guilford Press 2008.

42

Hubley J, Copeman J, Woodall J. Practical health promotion. 2nd ed. Cambridge: : Polity Press 2013.

43

Laverack G. Health promotion practice: building empowered communities. Maidenhead: : Open University Press 2007.
<https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,shib&db=nlebk&AN=234222&site=ehost-live&scope=site&custid=s8454451>

44

Macdowall W, Bonell C, Davies M. Health promotion practice. Maidenhead: : Open University Press 2006.

45

Walker R, Whittlesea C. Clinical pharmacy and therapeutics. 5th ed. Edinburgh: : Churchill Livingstone 2012.
<https://www.vlebooks.com/Product/Index/173020?page=0&startBookmarkId=-1>

46

Kumar PJ, Clark ML. Kumar & Clark's clinical medicine. 8th ed. Edinburgh: : Saunders Elsevier 2012. <https://www.dawsonera.com/abstract/9780702053047>

47

Greene RJ, Harris ND. Pathology and therapeutics for pharmacists: a basis for clinical pharmacy practice. 3rd ed. London: : Pharmaceutical Press 2008.

48

Coeliac disease: recognition, assessment and management | Guidance and guidelines | NICE. <https://www.nice.org.uk/guidance/ng20>

49

Chronic obstructive pulmonary disease.
<http://cks.nice.org.uk/chronic-obstructive-pulmonary-disease>

50

CPPE - Centre for Pharmacy Postgraduate Education. <https://www.cppe.ac.uk/>

51

Royal Pharmaceutical Society (RPS). <http://www.rpharms.com/home/home.asp>

52

Heart failure - chronic. <http://cks.nice.org.uk/heart-failure-chronic>

53

Medicines Use Review and Prescription Intervention service.
http://psnc.org.uk/wp-content/uploads/2013/06/MUR-service-spec-Aug-2013-changes_FINAL.pdf

54

Service specification - New Medicine Service (NMS).
http://psnc.org.uk/wp-content/uploads/2013/06/NMS-service-spec-Aug-2013-changes_FINAL.pdf

55

Commissioners and healthcare professionals - Training videos.
http://healthcheck.nhs.uk/commissioners_and_providers/training/training_videos1/

56

NHS Health Check - NHS Choices.
<http://www.nhs.uk/Conditions/nhs-health-check/Pages/NHS-Health-Check.aspx>